<DOC>
	<DOCNO>NCT00935025</DOCNO>
	<brief_summary>This phase I , single-blind , randomize , placebo-controlled single repeat ascend dose study assess safety , tolerability pharmacokinetics oral dos AZD1305 extended-release capsule healthy male Japanese Caucasian subject . Three ( four need ) dose level give Japanese subject one dose also give Caucasian subject .</brief_summary>
	<brief_title>AZD1305 Single Multiple Ascending Dose Study Healthy Japanese Caucasian Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy Japanese Caucasian male subject 20 45 year age inclusive Body weight 50 85 kg , inclusive , Body Mass Index ( BMI ) ≥19 ≤ 27 kg/m2 Clinically significant illness , surgical procedure trauma , within two week precede preentry visit first administration IP , judge investigator History clinically significant gastrointestinal , mental , cardiac , renal hepatic disorder , significant disease judge investigator Habitual smoker ( daily use ) tobacco daily use nicotinecontaining product</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Japanese healthy volunteer</keyword>
	<keyword>AZD1305</keyword>
	<keyword>Japanese Caucasian</keyword>
</DOC>